logo-loader
viewOragenics Inc

Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial

Oragenics (NYSE:OGEN) CEO Alan Joslyn caught up with Proactive at the BIO Investor Forum in San Francisco. 

Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.

Quick facts: Oragenics Inc

Price: 0.5149 USD

NYSE:OGEN
Market: NYSE
Market Cap: $23.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

25 minutes ago

2 min read